These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND SF3B1, ENSG00000115524, 23451, O75533, SF3b155, SAP155, PRPF10, PRP10
12 results:

  • 1. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
    Chen SH; Tse KP; Lu YJ; Chen SJ; Tian YF; Tan KT; Li CF
    Cancer Med; 2024 Jun; 13(12):e7384. PubMed ID: 38895905
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
    Pritchard AL; Johansson PA; Nathan V; Howlie M; Symmons J; Palmer JM; Hayward NK
    PLoS One; 2018; 13(4):e0194098. PubMed ID: 29641532
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Uncommon somatic mutations in metastatic NUT midline carcinoma.
    Cavalieri S; Stathis A; Fabbri A; Sonzogni A; Perrone F; Tamborini E; Pelosi G; de Braud F; Platania M
    Tumori; 2017 Nov; 103(Suppl. 1):e5-e8. PubMed ID: 28967088
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify.
    Komor MA; Pham TV; Hiemstra AC; Piersma SR; Bolijn AS; Schelfhorst T; Delis-van Diemen PM; Tijssen M; Sebra RP; Ashby M; Meijer GA; Jimenez CR; Fijneman RJA
    Mol Cell Proteomics; 2017 Oct; 16(10):1850-1863. PubMed ID: 28747380
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of recurrent mutational events in anorectal melanoma.
    Yang HM; Hsiao SJ; Schaeffer DF; Lai C; Remotti HE; Horst D; Mansukhani MM; Horst BA
    Mod Pathol; 2017 Feb; 30(2):286-296. PubMed ID: 27739435
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Alternative Splicing Detection as a Biomarker for cancer Diagnosis: A Novel Progressive Mechanism of Acute Lymphoblastic Leukemia with Alternative Splicing as a Biomarker Candidate].
    Kitamura K; Matsushita K; Kobayashi S; Ishige T; Semba T; Kimura A; Kazami T; Ohyama M; Itoga S; Beppu M; Nishimura M; Satoh M; Nomura F
    Rinsho Byori; 2015 Sep; 63(9):1091-102. PubMed ID: 26731899
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.
    Rahmutulla B; Matsushita K; Satoh M; Seimiya M; Tsuchida S; Kubo S; Shimada H; Ohtsuka M; Miyazaki M; Nomura F
    Oncotarget; 2014 May; 5(9):2404-17. PubMed ID: 24811221
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.
    Matsushita K; Shimada H; Ueda Y; Inoue M; Hasegawa M; Tomonaga T; Matsubara H; Nomura F
    World J Gastroenterol; 2014 Apr; 20(15):4316-28. PubMed ID: 24764668
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Interactions between sap155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.
    Matsushita K; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Levens D; He L; Liu J; Yoshida M; Nomura F
    Mol Cancer Res; 2013 Jul; 11(7):689-98. PubMed ID: 23594796
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. sap155-mediated c-myc suppressor far-upstream element-binding protein-interacting repressor splicing variants are activated in colon cancer tissues.
    Kajiwara T; Matsushita K; Itoga S; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Habara Y; Matsuo M; Nomura F
    Cancer Sci; 2013 Feb; 104(2):149-56. PubMed ID: 23113893
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. sap155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression.
    Matsushita K; Kajiwara T; Tamura M; Satoh M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Yoshimoto R; Ito A; Kubo S; Natsume T; Levens D; Yoshida M; Nomura F
    Mol Cancer Res; 2012 Jun; 10(6):787-99. PubMed ID: 22496461
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Biological validation that SF3b is a target of the antitumor macrolide pladienolide.
    Yokoi A; Kotake Y; Takahashi K; Kadowaki T; Matsumoto Y; Minoshima Y; Sugi NH; Sagane K; Hamaguchi M; Iwata M; Mizui Y
    FEBS J; 2011 Dec; 278(24):4870-80. PubMed ID: 21981285
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.